PLoS One 2014, 9(5): e97554
Monitor patients with a history of diabetic retinopathy
The peptide safety and risks overview provides broader context for evaluating long-term peptide therapy
Kidney Int Suppl 69:S93-106 Mercadal L, Coudert M, Vassault A, Pieroni L, Debure A, Ouziala M et al (2012) L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial
Chen X, Zaro JL, Shen WC (2013) Fusion protein linkers: property, design and functionality
with GLP-1 drugs causing diarrhea in up to ~30% and vomiting in up to ~24.5% of semaglutide users, persistent GI losses during dose escalation can drop serum potassium below 3.5 mEq/L (hypokalemia), causing muscle weakness, cramps, palpitations, and dangerous arrhythmias